The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

white-paper
FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections
Read More

post
When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall
Read More

infographic
Understanding the Stakes of IND Submissions: Why Timely Approvals Matter
Read More

post
291 FDA Complete Response Letters Decoded: Insights for Biologics CMC Strategy
Read More
Let's move from science to success.
Let’s Talk